8 In patients with T2D, semaglutide is effective in lowering blood sugar levels and promoting weight loss

Decreased appetite was also reported in 5% of patients taking semaglutide tablets The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation Ozempic injection: In placebo-controlled trials, discontinuation due to GI adverse reactions was 3.1% and 3.8% for the Ozempic injection 0.5 mg and 1 mg dose, respectively, compared with 0.4% for placebo Semaglutide tablets: 4% and 8% of patients discontinued semaglutide tablets 7 mg and 14 mg, respectively, due to GI adverse reactions, compared with 1% of patients receiving placebo Rates of hypoglycemia in placebo-controlled trials 1-3 Incidence of severe hypoglycemia was 300 mg/g at baseline) were randomized 1:1 to receive Ozempic injection 1 mg (n=1767) or placebo (n=1766) once-weekly, both in addition to standard-of-care treatments, including a maximum tolerated labeled dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent, including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment was contraindicated or not tolerated

Boxed warning and who should not use these medicines Both semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodent studies
Both HSA and FSA cards are accepted, along with major credit cards
Talk to Your Doctor or Pharmacist ASAP If you rely on Tirzepatide for weight loss or diabetes management, now is the time to explore alternatives
Monitor blood sugar if diabetic, as hypoglycemia can cause both headaches and dizziness